Comparative Safety Profiles of Anti-Amyloid Therapies in Early Alzheimer’s Disease (AD): A Detailed Systematic Review and Meta-Regression Analysis of Amyloid Related Imaging Abnormalities (ARIA) – Incidence and Infusion Reactions for Lecanemab, Donanemab, and Aducanumab
Aims: Alzheimer’s disease continues to be a huge health concern around the globe. Although similar recent developments in anti-amyloid therapy are promising, there is concern about some side effects like ARIA. The purpose of this meta-analysis was to systematically review and compare the safety char...
Saved in:
| Main Authors: | Sathyan Soundara Rajan, Sneh Babhulkar, Gaurav Uppal, Sharmi Bhattacharyya, Asha Devi Dhandapani |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Cambridge University Press
2025-06-01
|
| Series: | BJPsych Open |
| Online Access: | https://www.cambridge.org/core/product/identifier/S2056472425102354/type/journal_article |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Amyloid solutions: lecanemab, gantenerumab, and donanemab in the treatment of Alzheimer's disease
by: Taha basit Ameen, et al.
Published: (2025-05-01) -
In Elderly Patients With Antipsychotic-Induced Hyperprolactinemia, Could Switching to a Prolactin-Sparing Antipsychotic or Adding a Dopamine Agonist, Rather Than Maintaining the Current Regimen, Normalize the Prolactin Levels Without Triggering Psychotic Relapse or Increasing the Risk of Life-Threatening Adverse Events? A Systematic Review
by: Gaurav Uppal, et al.
Published: (2025-06-01) -
Monoclonal antibodies against beta-amyloid protein (lecanemab and donanemab) should not be used in the treatment of Alzheimer's disease
by: Ricardo Nitrini, et al.
Published: (2025-05-01) -
Slumber’s Duel: The Upstart Orexin Receptor Antagonists Versus the Battle-Hardened Z-Drugs: Systematic Review and Meta-Analysis Unveiling a Tale of Efficacy and Safety of Two Contenders
by: Asha Devi Dhandapani, et al.
Published: (2025-06-01) -
Clinical efficacy of anti‐amyloid antibodies in apolipoprotein E ε4 homozygotes: A Bayesian reanalysis of lecanemab and donanemab phase 3 results
by: Stefan Teipel, et al.
Published: (2025-04-01)